Stereotactic body radiotherapy in the treatment of adrenal metastases

Kamran A. Ahmed, Brandon M. Barney, O. Kenneth Macdonald, Robert C. Miller, Yolanda I. Garces, Nadia N. Laack, Michael G. Haddock, Robert L. Foote, Kenneth R. Olivier

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

OBJECTIVES:: To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases. MATERIALS AND METHODS:: From February 2009 to February 2011, a total of 13 patients were treated with SBRT for metastases to the adrenal glands. Median age was 71 years (range, 60.8 to 83.2). Primary sites included lung (n=6), kidney (n=2), skin (n=2), bladder (n=1), colon (n=1), and liver (n=1). Nine patients had metastases to the left adrenal gland and 4 to the right. The median prescribed total dose was 45 Gy (range, 33.75 to 60 Gy), all in 5 fractions. RESULTS:: Median follow-up for living patients was 12.3 months (range, 3.1 to 18 mo). Twelve of the 13 patients (92.3%) were evaluable for local control (LC). The crude LC rate was 100%, with no cases of local or marginal failure. Two patients had a complete response to treatment, 9 patients had a partial response, and 1 patient displayed stable disease. One-year overall survival and distant control were 62.9% and 55%, respectively. Median OS was 7.2 months (range, 2 to 18 mo). Grade 2 nausea was noted in 2 patients. CONCLUSIONS:: SBRT seems to be a safe and effective measure to achieve LC for adrenal metastases.

Original languageEnglish (US)
Pages (from-to)509-513
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume36
Issue number5
DOIs
StatePublished - Oct 1 2013

Keywords

  • Adrenal metastases
  • Intensity-modulated radiotherapy
  • Stereotactic body radiation therapy
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Stereotactic body radiotherapy in the treatment of adrenal metastases'. Together they form a unique fingerprint.

  • Cite this